FindTrial
Sign In

Randomised trial in newly diagnosed Hodgkin's disease: evaluation of drug scheduling (alternating LOPP/EVAP versus LOPP/EVA hybrid) and consolidation radiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN97767916
Enrollment
Unknown
Registered
2001-07-01
Start date
1999-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin's Lymphoma Cancer Hodgkin's Lymphoma

Interventions

1. Regimen A: Chemotherapy, chlorambucil vincristine, procarbazine and prednisolone (LOPP) alternating every 28 days with etoposide, vinblastine, adriamycin and prednisolone (EVAP). A course of chemot

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged over 15 years 2. Stage IB, IIB, III or IV Hodgkin's Disease. 3. Histologically confirmed Hodgkin's lymphoma 4. Free from any potentially life threatening disease other than Hodgkin's Disease 5. Lymphangiography or Computed Tomography (CT) scan of the abdomen 6. No previous treatment except as an emergency measure

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026